Pitolisant, a treatment for narcolepsy, should be considered for people with Prader-Willi syndrome (PWS) whose response to psychotropic medications…
Articles by Forest Ray PhD
9 Meters Biopharma acquired global development rights to NM-136, a potential Prader-Willi syndrome (PWS) therapy, from its maker,…
An additional clinical trial into diazoxide choline controlled release (DCCR) tablets as a potential treatment for the insatiable hunger associated…
The U.S. Food and Drug Administration (FDA) has granted priority review to LV-101 (intranasal carbetocin), an investigational treatment for…
The Foundation for Prader-Willi Research (FPWR) announced its support for ARD-101, an investigational, gut-targeting Prader-Willi syndrome (PWS) therapy, by…
Editor’s Note: This is the second of two articles looking at DCCR, Soleno Therapeutics’ investigational treatment, and the DESTINY-PWS trial. The first…
Diazoxide choline controlled release (DCCR) tablets are an investigational therapy for Prader-Willi syndrome (PWS) that, according to data…
A planned Phase 2b trial of Tesomet in treating Prader-Willi syndrome (PWS) is being pushed back to later this year,…
The excessive eating experienced by people with Prader-Willi syndrome (PWS) intimately affects the burden felt by their caregivers, according…
The Foundation for Prader-Willi Research (FPWR) and Saniona are working together to inform patients and their families of an upcoming…